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Abstract
Background: To date, antiretroviral therapy (ART) guidelines and programs in resource-limited settings (RLS) have focused
on 1
st- and 2
nd-line (2 L) therapy. As programs approach a decade of implementation, policy regarding access to 3
rd-line
(3 L) ART is needed. We aimed to examine the impact of maintaining patients on failing 2 L ART on the accumulation of
protease (PR) mutations.
Methods and Findings: From 2004–2011, the Harvard/APIN PEPFAR Program provided ART to .100,000 people in Nigeria.
Genotypic resistance testing was performed on a subset of patients experiencing 2 L failure, defined as 2 consecutive viral
loads (VL).1000 copies/mL after $6 months on 2 L. Of 6714 patients who received protease inhibitor (PI)-based ART, 673
(10.0%) met virologic failure criteria. Genotypes were performed on 61 samples. Patients on non-suppressive 2 L therapy for
,12 months prior to genotyping had a median of 2 (IQR: 0–5) International AIDS Society (IAS) PR mutations compared with
5 (IQR: 0–6) among patients failing for .24 months. Patients developed a median of 0.6 (IQR: 0–1.4) IAS PR mutations per 6
months on failing 2 L therapy. In 38% of failing patients no PR mutations were present. For patients failing .24 months,
high- or intermediate-level resistance to lopinavir and atazanavir was present in 63%, with 5% to darunavir.
Conclusions: This is the first report assessing the impact of duration of non-suppressive 2 L therapy on the accumulation of
PR resistance in a RLS. This information provides insight into the resistance cost of failing to switch non-suppressive 2 L
regimens and highlights the issue of 3 L access.
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Introduction
Over 8 million individuals living with HIV in low- and middle-
income countries are receiving antiretroviral therapy (ART) [1].
As large-scale ART programs in resource-limited settings (RLS)
approach a decade of implementation, the 2010 World Health
Organization (WHO) public health guidelines for the first time
raised the issue of access to third-line ART and called on national
programs to delineate policies [2].
As with access pricing for first-line (1 L) and second-line (2 L)
ART, the cost of third-line (3 L) ART has decreased nearly ten-
fold in the past several years [3]. However, it is yet to be
determined whether there is a significant need for 3 L ART
among patients in RLS. Published rates of 2 L failure vary,
ranging from as low as 14.3% at 24 months follow-up [4] to as
high as 50% of patients with confirmed virologic failure [5–10]. A
number of studies suggest that the majority of patients who fail 2 L
ART do so with minimal drug resistance, suggesting poor
adherence rather than resistance as the cause of failure. In one
study, wild-type virus was present at the time of failure in up to
67% of patients with no major protease (PR) mutations identified
[11–12]. However, studies vary widely, with 28% of patients
harboring at least one PR mutation after 2 L failure in a study
from Mali [13], in contrast to 73% of 2 L failures in a cohort from
India [14].
The variability is not surprising given differences in duration of
failure prior to genotype testing among the studies. To date,
studies have been limited by either a short or unknown duration of
follow-up on failing 2 L regimens. Although resistance to non-
nucleoside reverse transcriptase inhibitors (NNRTI) develops
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e73582rapidly and for those NNRTIs utilized in 1 L regimens only
requires a single point mutation [15,16], resistance to protease
inhibitors (PI) requires sequential accumulation of mutations in the
setting of ongoing exposure to non-suppressive PI-based ART
[17].
Additionally, after failure of 1 L ART, 2 L options may be
limited in settings where nucleoside reverse transcriptase inhibitors
(NRTI) are restricted [18]. In one study, failure of a PI-based 2 L
regimen was more closely associated with failure to change the
NRTI backbone rather than level of adherence [19]. Decreased
susceptibility to the NRTI component of a regimen may,
therefore, increase the risk of developing PI resistance [20,21].
Here, we report on rates of 2 L treatment failure from a large
ART program in Nigeria, with a focus on the accumulation of PR
mutations according to time on failing 2 L ART among a subset of
patients who underwent genotype testing. Additionally, we present
the first outcome data from a small cohort of patients receiving 3 L
ART in Nigeria. The challenge remains to determine how, or
perhaps whether, policy makers, implementing partners, national
governments, and pharmaceutical companies will address the
inevitable need for 3 L therapy among patients living in RLS.
Methods
Study Setting
The Harvard/AIDS Prevention Initiative in Nigeria (APIN)
President’s Emergency Plan for AIDS Relief (PEPFAR) program
provided HIV treatment to over 100,000 individuals at 32 clinical
sites in Nigeria from 2004–2011. Consistent with the Nigerian
national [22] and WHO treatment guidelines [2,23], 1 L ART
consisted of one NNRTI plus two NRTIs. Second-line ART
consisted of a ritonavir-boosted PI plus 2 NRTIs (selected to differ
from those used in 1 L regimen). In this retrospective analysis, the
study cohort consisted of HIV-infected adults for whom 2 L failure
was confirmed and genotype testing was performed.
Ethical Considerations
All patients enrolled in the Harvard/APIN PEPFAR program
provided written consent for care; data for those that also
consented for use of their information in future analyses were
evaluated. The treatment protocol and written consent were
approved by the institutional review boards (IRBs) of the Harvard
School of Public Health and by each of the affiliated treatment
sites. All program-affiliated Nigerian IRBs are registered with the
U.S. Federalwide Assurance.
Definition of Treatment Failure and Selection Criteria for
Genotyping
Based on the program protocol, virologic failure was defined as
two consecutive viral load (VL) measurements .1000 copies/mL
(cpm) after at least 6 months of ART. For patients failing a 2 L
regimen, genotypic resistance testing was considered if adequate
adherence was demonstrated. Adequacy of adherence was
determined by individual clinicians and typically required .95%
adherence to the pharmacy pick-up schedule during the 3–6
months prior to the last detectable VL measurement.
The duration of 2 L failure was based on either the time from 2 L
initiation to genotype testing, if the patient never achieved
virologic suppression, or the time from last suppressed VL to
genotype testing for those who initially achieved suppression on
2 L. The overall duration of 2 L ART was also determined,
representing time from 2 L initiation to genotype testing in this
study.
Adherence Assessment
Adherence was estimated using pharmacy pickup data. Patients
were given either a 30- or 60-day supply of ART, and average
adherence was calculated as the proportion of time the patient had
pills available to them from 2 L initiation to the date of
genotyping. For instance, if a patient presented early to collect
the prescription one month, this excess pill supply was accounted
for during subsequent pick-ups.
Data Collection
Patient data were collected on paper clinic forms and
prescription pads. The data were then entered into a customized
electronic record database by trained data staff at each site.
Baseline evaluations included medical history, physical examina-
tion, WHO clinical staging, CD4+ cell count, plasma VL,
complete blood counts, and chemistries. These same clinical and
laboratory evaluations were performed 3 and 6 months after ART
Table 1. Patient Characteristics by Duration of Second-Line Treatment Failure.
Duration of Second-Line Failure
a
0–12 months 13–24 months .24 months All Patients
Characteristic (n=13) (n=29) (n=19) (n=61)
Age (years) 42 (32–44)
b 38 (33–42) 40 (32–49) 40 (32–44)
Gender, female (%) 38% 35% 63% 44%
# ARVs previously used, median (range) 6 (4–7) 6 (4–8) 6 (5–9) 6 (5–9)
Duration on 1 L (months) 22 (19–36) 28 (21–36) 17 (15–26) 25 (16–34)
Duration on 2 L (months)
c 13 (11–38) 20 (18–26) 39 (34–47) 26 (18–38)
Duration of 2 L Failure (months)
a 11 (6–11) 17 (16–20) 34 (30–42) 19 (13–28)
Adherence to 2 L (%), median 88 (77–100) 96 (85–100) 93 (81–100) 93 (81–100)
CD4 at 2 L failure (cells/mm
3) 208 (108–269) 225 (118–296) 205 (108–304) 215 (116–291)
VL at 2 L failure (copies/mL) 29,068 (7,918–130,037) 7,830 (3,264–22,696) 75,600 (1,989–195,879) 13,835 (2,954–99,344)
aTime from 2 L initiation, or last suppressed VL on 2 L, to genotype sample.
bNumbers represent: Median (IQR) unless otherwise indicated.
cTime from 2 L initiation to genotype sample.
doi:10.1371/journal.pone.0073582.t001
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symptoms required more frequent monitoring. Additionally,
pharmacists entered dispensing information directly into a
customized electronic database that mirrors the prescription pad,
providing real-time visual confirmation of patient pharmacy refill
history.
Laboratory Analysis
All laboratory tests were performed in Nigeria by trained
laboratory staff at each clinic facility. CD4+ cell count measure-
ment was performed using laser-based CD4 T-lymphocyte
enumeration (Cyflow, Partec, Germany). Plasma HIV-1 RNA
VL determination was performed using the Roche Cobas
Amplicor Monitor assay, version 1.5 (Roche Diagnostics, New
Jersey, USA). All laboratories participate in regular external
quality-control programs for HIV diagnosis, CD4+ cell enumer-
ation, and plasma VL estimation.
Genotype Testing
Starting in 2008, the Harvard/APIN PEPFAR program began
developing the laboratory infrastructure to perform HIV genotype
testing at three sites in Nigeria including, Jos University Teaching
Hospital in Jos, Plateau State, University College Hospital in
Ibadan, Oyo State, and the Nigerian Institute of Medical Research
in Lagos, Lagos State. Drug resistance genotyping was performed
on a 3130 ABI sequencer (Applied Biosystems, Foster City, CA,
USA) using the Viroseq HIV-1 Genotyping system (Abbott
Molecular, Des Plaines, IL, USA) to reverse transcribe and
amplify 297 bases of the PR and 1005 bases of reverse
transcriptase (RT) genes. Sequence was edited and compared to
an HXB2 subtype B reference with the manufacturer’s software to
generate lists of mutations and polymorphisms. Sequences were
aligned in ClustalW (Belfield, Dublin, Ireland) along with
reference sequences from the Los Alamos repository [24] and
neighbor-joining trees were used to classify them by subtype.
The clinical significance of identified drug resistance mutations
was determined using the Stanford HIV Drug Resistance
Database and the 2011 version of the International AIDS Society
(IAS) drug resistance update [25,26]. The estimated rate of
accumulation of PR mutations was calculated by dividing the total
number of major and minor IAS PR mutations by the duration of
2 L failure.
Genotype sensitivity scores (GSS) for the prescribed regimen at
the time of 2 L failure were calculated based on the five Stanford
HIVdb resistance categories: susceptible or complete activity,
potential low-level resistance or good activity, low-level resistance
or partial activity, intermediate-level resistance or scarce activity,
high-level resistance or no activity corresponding with scores of
1.00, 0.75, 0.50, 0.25, and 0.00, respectively [25,27].
Third-line Treatment
A small number of patients with 2 L failure and evidence of
extensive PR resistance were initiated on 3 L ART. Appropriate
3 L regimens were determined based on resistance profiles and the
availability of a limited supply of 3 L drugs, most commonly
consisting of a combination of darunavir/ritonavir (DRV/r),
raltegravir (RAL), recycled nucleosides, and, in cases where
indicated, etravirine (ETR).
Statistical Analyses
Statistical analyses were performed using Stata version 10.1
(StataCorp, College Station, TX). For continuous variables, the
nonparametric Wilcoxon test was used due to small sample sizes
and lack of normally distributed data. The Fisher’s exact test was
used for categorical variables. Variables at the p,0.05 were
considered statistically significant.
Results
Study Population
Since the program began in 2004, over 100,000 patients have
initiated ART within the Harvard/APIN PEPFAR program. Of
Table 2. Accumulation of Protease Mutations According to Duration of Second-Line Treatment Failure.
Duration of Second-Line Failure
0–12 months 13–24 months .24 months All Patients
Characteristic (n=13) (n=29) (n=19) (n=61)
Patients with $1 IAS PR mutation, n (%) 8 (62%) 16 (55%) 14 (74%) 38 (62%)
# Protease mutations, median (IQR) 2 (0–5) 1 (0–4) 5 (0–6) 2 (0–5)
Major PR mutations (IAS) 2 (0–3) 0 (0–3) 3 (0–4) 1 (0–3)
Minor PR mutations 0 (0–1) 0 (0–2) 2 (0–3) 1 (0–2)
Patients with no PR mutations, n (%) 5 (38%) 13 (45%) 5 (26%) 23 (38%)
High- or Intermediate-level PI Resistance, n (%)
Lopinavir (LPV/r) 7 (54%) 11 (38%) 12 (63%) 30 (49%)
Atazanavir (ATV/r) 5 (38%) 11 (38%) 12 (63%) 28 (46%)
Darunavir (DRV/r) 0 (0%) 4 (14%) 1 (5%) 5 (8%)
Genotypic Sensitive Score 1 (0.25–3) 1.25 (0.5–4) 0.5 (0.25–1.5) 1.25 (0.25–3)
# PR mutations for every 6 mo. on Failing 2 L Regimen
(n=61)
2.0 (0–3.0) 0.3 (0–1.4) 0.8 (0.1–1.1) 0.6 (0–1.4)
# PR mutations for every 6 mo. on Failing 2 L Regimen
(n=38, patients with no PR mutations excluded)
(n=8) (n=16) (n=14) (n=38)
2.9 (2.3–3.5) 1.3 (0.6–2.4) 1.0 (0.7–1.2) 1.2 (0.8–2.4)
doi:10.1371/journal.pone.0073582.t002
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therapy. Of patients receiving 2 L ART, 673 (10.0%) met the
program-defined virologic failure criteria of 2 consecutive
VLs.1000 cpm. Of note, if a VL failure definition of confirmed
VL.5000 cpm, as is consistent with the 2010 WHO guidelines
[1], had been utilized, the number of patients characterized as
failures would have decreased to 354 individuals (5.3%; 52.6% of
673 failures), with the diagnosis of failure being delayed a mean of
7.6 months in 50 of those patients.
Genotypes were performed on 61 patient samples. In general,
patients selected for genotyping were more immunocompromised,
but more adherent, and had been on 2 L ART for longer than
those who were not selected. Comparing the 61 patients for whom
genotypes were performed to the 612 patients who failed, but were
not selected for genotype testing, the median CD4+ cell count was
215 cells/mm
3 (IQR: 116–291) versus 265 cells/mm
3 (IQR: 158–
429; p=0.006) and the median 2 L adherence was 93% versus
88% (p=0.008), respectively. The total duration of 2 L ART was
3.9 years (IQR: 2.9–4.8) versus 3.2 years (IQR: 2.4–4.2;
p=0.003), respectively. Total antiretroviral exposure was similar
for the patients who underwent genotype testing versus those who
did not, with the median number of prior antiretroviral drugs
being 6 (IQR: 5–9) versus 6 (IQR: 5–6).
Results from the 61 patients who underwent genotype testing
were stratified by time on failing 2 L regimen (0–12 months
(n=13), 13–24 months (n=29), and .24 months (n=19);
Table 1). All patients were receiving lopinavir/ritonavir (LPV/r)
at the time of 2 L failure, although prior exposure to saquinavir,
indinavir, or both occurred in 10% (n=6), 7% (n=4), and 2%
(n=1), respectively. Overall, the median duration on 1 L ART
prior to 2 L switch was 25 months (IQR: 16–34 months) and
median patient age at time of 2 L initiation was 40 years (IQR:
32–44 years). The aggregate patient characteristics at the time of
2 L failure included: median CD4+ cell count of 215 cells/mm
3,
median VL of 13,835 cpm, median duration of 2 L failure of 19
months (IQR: 13–28 months), and 44% of the cohort was female.
Accumulation of Protease Mutations
Among patients who had been failing 2 L ART for .24
months, the median number of IAS PR mutations was 5 (IQR: 0–
Figure 1. Frequency of protease (PR) mutations among 61 patients failing second-line ART. (A) Total prevalence of PR mutations. Major
PR mutations are in black, minor PR mutations are in dark grey, and polymorphisms (mutation position labeled with *) are in light grey. (B) Prevalence
of PR mutations stratified by time on failing second-line regimen.
doi:10.1371/journal.pone.0073582.g001
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and 2 (IQR: 0–5) for those failing for #12 months. Using these
cross-sectional data, we estimated that patients developed a
median of 0.6 (IQR: 0–1.3) IAS PR mutations for every 6 months
on a failing 2 L regimen (Table 2).
Although 62% of patients had one or more PR mutations, wild-
type virus (no RT or PR mutations) was present in 18% of patients
with genotypes, while 20% of failing patients had at least one RT
mutation but no PR mutations. Since the acquisition of PR
mutations is a progressive process [17,28,29], where patients with
established PR resistance are more likely to acquire additional PI
mutations, we also examined the rate of accumulation among the
38 patients with at least one major or minor PI mutation. Among
this subset of patients, the median number of IAS PR mutations
for every 6 months on a failing 2 L regimen increased to 1.2 (IQR:
0.8–2.4).
For patients failing .24 months, high- or intermediate-level
resistance to LPV/r and atazanavir/ritonavir (ATV/r) was present
in 63% of patients and to DRV/r in 5% of patients. Among the 61
patients, the median GSS for the 2 L regimen was 1.25 (IQR:
0.25–3) (Table 2).
Distribution of Drug Resistance Mutations
The distribution of HIV-1 subtypes included: CRF02_AG
(41%, n=25), G-prime (34%, n=21), CRF06_cpx (7%, n=4), G
(5%, n=3), one patient each with subtype C, A3, and CRF22; the
subtype was unknown in 8% (n=5). The most common major PR
mutations included: I54V/A/S (n=28, 46%), V82A/F/T/S/M
(n=25, 41%), M46I/L (n=21, 34%), L76V (n=8, 13%), and
G48V/M/Q (n=7, 11%) (Figure 1). A number of PR polymor-
phisms common among non-subtype B virus were also identified,
consistent with previous studies [16,30]. Those polymorphisms
present in .90% of patients in this cohort included: V3I, I13V/
A/M, K20I/V/M/R/T/L, M36I/L/V, S37N/D/E/K, H69K/
E/R/S and L89M/I (Figure 1).
At least one thymidine analog mutation (TAM) was present in
56% of patients at the time of genotype testing, with 44% (27
patients) having 3 or more TAMs (Figure 2). Among the 38
patients with 1 or more IAS PR mutations, all but 2 patients had at
Figure 2. Prevalence of reverse transcriptase mutations. (A) NRTI resistance mutations; thymidine analog mutations (TAMs) are in light grey.
(B) NNRTI resistance mutations; minor mutations indicated by light grey.
doi:10.1371/journal.pone.0073582.g002
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likely underestimate archived resistance given that patients had
been off NNRTI-based therapy for varying durations. However,
28% (17 of 61) had high- or intermediate-level resistance to ETR
at the time of genotype.
Third -Line ART Program Experience
Among this cohort of 61 patients, 11 patients with documented
high-level resistance to LPV/r initiated 3 L ART (Table 3). All 11
patients initiated a 3 L regimen containing DRV/r and RAL, with
6 patients also receiving ETR and 8 patients receiving recycled
NRTIs, based on drug resistance profiles. At a median of 31
months after initiating 3 L ART (IQR: 29–39 months), 9 of 11
patients remained virologically suppressed (VL,400 cpm). One
patient died within 6 months of initiating 3 L ART due to
complications of tuberculosis, sepsis, and renal failure. This
corresponds with a suppression rate of 82% after a median of
2.6 years on 3 L ART.
Discussion
This is one of the first reports to evaluate the rate of
accumulation of PR mutations following 2 L failure in a RLS.
Among patients failing 2 L ART for over 24 months, almost two-
thirds developed regimen-compromising PR resistance with a
median of five IAS PR mutations. On average, we estimated that
patients developed 0.6 PR mutations for every 6 months they were
maintained on a failing 2 L regimen.
A number of prior studies from RLS have reported low rates of
PR resistance after 2 L failure [11,31,32], often attributing this
finding to poor medication adherence. Although failure of PI-
based ART without evidence of drug resistance is a well-
documented phenomenon, and may be attributed to the relatively
narrower range of adherence levels at which PI resistance develops
[17,33], these findings may be partially attributed to the short
duration of 2 L ART exposure in these studies. In contrast, over
60% of patients in this study had one or more IAS PR mutation,
placing them at increased risk of accumulating additional PI
mutations.
Although the importance of intensified adherence counseling
within programs cannot be overemphasized, for some patients,
maintaining a failing 2 L ART regimen will result in increasingly
resistant virus. This study was not intended to evaluate overall
resistance among patients with 2 L failure, rather to assess the
prevalence of PR mutations among patients identified by clinic-
based practitioners as experiencing virologic failure in the setting
of good adherence. The challenge in RLS remains how to
determine which patients are failing due to non-adherence versus
the presence of drug resistance mutations.
This analysis documented that over two-thirds of patients
developed PR mutations at positions 46, 54, or 82, which have
been associated with the rapid development of lopinavir resistance
in prior studies [28]. Given the known cumulative nature of PR
resistance [17,28], one would expect increasing numbers of PR
mutations over time, as was demonstrated in this study. Adding to
the concern of suboptimal treatment, 44% of patients in this study
had 3 or more TAMs and the median GSS at genotype testing was
1.25 (IQR: 0.25–3). Among the 32 patients with full susceptibility
or only low-level LPV/r resistance, over one-third (11 of 32
patients) had significantly reduced activity of the NRTI backbone,
suggesting that the patients were effectively receiving LPV/r
monotherapy. LPV/r monotherapy has been shown in a number
of studies to be suboptimal [34–36], and may increase the risk for
resistance to PIs [37].
The majority of patients had preserved susceptibility to DRV/r,
suggesting that 3 L therapy may be an option; however, 28% (17
of 61) had high- or intermediate-level resistance to ETR. As access
pricing for 3 L ART continues to decline, with current estimates
for a regimen of DRV/r, ETR, RAL and recycled nucleosides
being approximately $2500 (in 2012 US dollars) per patient per
year [3], and longevity of ART programs increases, the national
government policy on 3 L access becomes ever more critical. Cost-
effectiveness evaluations of 1 L and 2 L ART in RLS have
consistently shown that access to ART is highly cost-effective
[38,39]. Formal cost analyses that include access to 3 L ART are
needed.
Several study limitations should be mentioned. First, data
regarding the clinical applicability of resistance mutations among
the multiple HIV-1 subtypes occurring in Nigeria are limited.
Thus, clinical assessments in this study were based on the Stanford
HIV Resistance Database, which primarily utilizes data from
subtype B virus. Additionally, accumulation of resistance muta-
tions over time was based on between patient comparisons.
Further studies examining intra-patient development of drug
resistance mutations over time would strengthen the determination
of rates of accumulation of PR mutations. Furthermore, the
relatively small sample size of 61 genotypes may limit broader
interpretation as rates of resistance accumulation are sensitive to
patient selection characteristics. The selection criteria for genotype
testing also required high levels adherence prior to testing, thus
this analysis was restricted to a somewhat more adherent patient
population. In addition, duration of failure and timing of genotype
assays were limited to those VL measurements collected as part of
routine clinical care. However, patients in this cohort were
monitored relatively frequently, with an average of one VL
evaluation every 4.9 months. Finally, we utilized population
genotyping, thus minor variants were potentially missed.
Finally, in this report we have also provided the first outcome
data on a cohort of patients receiving 3 L ART in sub-Saharan
Africa. Although the small cohort size limits wider assumptions of
efficacy, the preliminary outcomes suggest that 3 L therapy can be
effectively implemented in a RLS with excellent rates of virologic
suppression.
Table 3. Characteristics for Patients who Initiated Third-Line
ART.
Median (IQR)
c
Characteristic (n=11)
Age at 3 L Initiation (years) 48 (45–52)
Gender, female (%) 36%
# ARVs previously used, median
(range)
6 (4–7)
Duration on 1 L, months 23 (12–33)
Duration on 2 L, months 28 (16–36)
Duration of 2 L Failure
d, months 20 (14–35)
Adherence to 2 L (%), median 89 (76–100)
CD4 at 3 L switch (cells/mm
3) 75 (41–120)
VL at 3 L switch (copies/mL) 111,749 (14807–482,472)
Total # of IAS Protease mutations 6 (6–7.5)
Genotypic Sensitive Score 0.25 (0.125–0.25)
cResults represent median (IQR) except where indicated.
dTime from 2 L initiation, or last suppressed VL on 2 L, to genotype sample.
doi:10.1371/journal.pone.0073582.t003
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suppressive 2 L ART accumulate increasing numbers of PR
mutations over time, potentially compromising future ART
options. In this cohort, nearly two-thirds of patients failing for
more than 24 months had high- or intermediate-level LPV/r
resistance. As ART programs in RLS continue to mature, there
will be an increasing number of patients in need of 3 L treatment.
Development of policy by governments and their partners is
urgently required to address this emerging need.
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